The group's principal activity is to discover, develop and commercialize pharmaceutical products to prevent and treat diseases. The group is developing a portfolio of vaccines against viral and bacterial diseases, including single-dose oral vaccines aimed at protecting travelers and people in endemic regions from cholera, typhoid fever and other illnesses. The group's current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare and vaccines addressing human food safety and animal health. In addition, the group is conducting clinical studies of a proprietary vaccine candidate for cholesterol management.
